Tower Research Capital LLC (Trc) Corvus Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.36 - $2.29 $5,153 - $8,676	3,789 Added 32.92%	15,300 $27,000
Q1 2024 May 15, 2024	BUY	$1.76 - $2.41 $5,294 - $7,249	3,008 Added 35.38%	11,511 $20,000
Q4 2023 Feb 13, 2024	SELL	$1.08 - $1.92 $17,532 - $31,169	-16,234 Reduced 65.63%	8,503 $14,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.97 $5,913 - $12,456	4,194 Added 20.42%	24,737 $36,000
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $7,946 - $30,671	7,946 Added 63.08%	20,543 $47,000
Q1 2023 May 09, 2023	SELL	$0.65 - $0.92 $78 - $111	-121 Reduced 0.95%	12,597 $11,000
Q4 2022 Feb 10, 2023	BUY	$0.74 - $1.04 $777 - $1,092	1,050 Added 9.0%	12,718 $11,000
Q3 2022 Nov 10, 2022	BUY	$0.71 - $1.17 $1,657 - $2,731	2,335 Added 25.02%	11,668 $10,000
Q2 2022 Aug 15, 2022	BUY	$0.87 - $2.03 $5,534 - $12,912	6,361 Added 214.03%	9,333 $9,000
Q1 2022 May 12, 2022	SELL	$1.46 - $2.48 $21,304 - $36,188	-14,592 Reduced 83.08%	2,972 $5,000
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $8,505 - $19,301	-3,635 Reduced 17.15%	17,564 $42,000
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $25,600 - $115,538	13,545 Added 176.97%	21,199 $102,000
Q2 2021 Aug 16, 2021	SELL	$2.46 - $3.14 $86,424 - $110,314	-35,132 Reduced 82.11%	7,654 $20,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.77 $119,805 - $199,815	41,890 Added 4675.22%	42,786 $132,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $4.86 $19,772 - $26,992	-5,554 Reduced 86.11%	896 $3,000
Q3 2020 Nov 16, 2020	BUY	$2.6 - $5.37 $11,949 - $24,680	4,596 Added 247.9%	6,450 $26,000
Q2 2020 Aug 13, 2020	BUY	$2.01 - $4.05 $3,324 - $6,698	1,654 Added 827.0%	1,854 $5,000
Q1 2020 May 15, 2020	BUY	$1.74 - $5.98 $348 - $1,196	200 New	200 $0
Q4 2019 Feb 07, 2020	SELL	$2.56 - $5.44 $5,496 - $11,679	-2,147 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$3.01 - $6.5 $6,462 - $13,955	2,147 New	2,147 $6,000
Q2 2019 Aug 13, 2019	SELL	$3.3 - $4.58 $1,346 - $1,868	-408 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$3.75 - $4.97 $39,007 - $51,697	-10,402 Reduced 96.23%	408 $2,000
Q4 2018 Feb 14, 2019	BUY	$3.29 - $8.94 $30,070 - $81,711	9,140 Added 547.31%	10,810 $40,000
Q3 2018 Nov 13, 2018	BUY	$8.58 - $11.4 $1,175 - $1,561	137 Added 8.94%	1,670 $14,000
Q2 2018 Aug 15, 2018	SELL	$9.42 - $13.73 $19,782 - $28,833	-2,100 Reduced 57.8%	1,533 $17,000
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $15,812 - $24,374	2,114 Added 139.17%	3,633 $42,000
Q4 2017 Feb 09, 2018	SELL	$9.3 - $16.93 $6,956 - $12,663	-748 Reduced 33.0%	1,519 $16,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $25,617 - $39,060	2,267	2,267 $37,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

Orbimed Advisors LLC San Diego, CA

6.94M
Shares

$33.3 Million
0.86% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

5.56M
Shares

$26.7 Million
0.08% of portfolio
Samlyn Capital, LLC New York, NY

4.53M
Shares

$21.7 Million
0.39% of portfolio
Adams Street Partners LLC Chicago, IL

3.28M
Shares

$15.7 Million
10.6% of portfolio
Vanguard Group Inc Valley Forge, PA

2.42M
Shares

$11.6 Million
0.0% of portfolio

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account